{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T20:10:35Z","timestamp":1778789435942,"version":"3.51.4"},"reference-count":39,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"5","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Precis Oncol"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:sec>\n                    <jats:title>PURPOSE<\/jats:title>\n                    <jats:p>We sought to characterize outcome associations of poly ADP-ribose polymerase inhibitors (PARPi) in patients with ovarian cancer (OVCA) whose cancers contain homozygous loss (deletions) of homologous recombination repair (HRR) pathway genes, an alteration class not uniformly reported on clinical testing and not susceptible to acquired resistance via secondary reversion mutations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>\n                      This study used US-based deidentified Flatiron Health-Foundation Medicine OVCA Clinico-Genomic Database. Patients with advanced OVCA and genomic profiling by Foundation Medicine were assembled into cohorts evaluating PARPi monotherapy use, and separately, PARPi maintenance therapy use, with outcomes associated with HRR gene alterations:\n                      <jats:italic toggle=\"yes\">BRCA1<\/jats:italic>\n                      \/\n                      <jats:italic toggle=\"yes\">2<\/jats:italic>\n                      ,\n                      <jats:italic toggle=\"yes\">PALB2<\/jats:italic>\n                      ,\n                      <jats:italic toggle=\"yes\">RAD51B\/C\/D<\/jats:italic>\n                      ,\n                      <jats:italic toggle=\"yes\">BARD1<\/jats:italic>\n                      , and\n                      <jats:italic toggle=\"yes\">BRIP1<\/jats:italic>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      1.5% (82\/5,404) had HRR gene homozygous loss, with\n                      <jats:italic toggle=\"yes\">BRCA1<\/jats:italic>\n                      and\n                      <jats:italic toggle=\"yes\">BRCA2<\/jats:italic>\n                      loss being most common. Among all OVCAs with BRCA1\/2 alterations, 7.5% (63\/836) were homozygous losses. Most BRCA1 (34\/38, 89%) and BRCA2 (18\/25, 72%) homozygous losses were intragenic, with breakpoints not spanning entire gene. Maintenance cohort: 22 patients had HRR gene homozygous loss, with strongly improved progression-free survival (PFS) for PARPi versus no PARPi use (HR, 0.06, 95% CI, 0.01 to 0.37). Monotherapy cohort: patients without HRR alterations (n = 198), HRR mutations or rearrangements (n = 93), and HRR homozygous loss (n = 8) had median PFS of 4.9, 10.6, and 25.4 months, and median overall survival of 18.5, 22.5, and 51.8 months, respectively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>We observe durable PARPi effectiveness for patients with OVCA and HRR gene homozygous loss in routine practice. We demonstrate the importance of detecting and reporting homozygous loss in HRR genes, an aspect not standard to all sequencing assays.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/po-25-00763","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T19:59:11Z","timestamp":1778788751000},"update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":0,"title":["Homozygous Loss of Recombination Repair Genes and Poly ADP-Ribose Polymerase Inhibitor Benefit for Patients With Ovarian Cancer"],"prefix":"10.1200","volume":"10","author":[{"given":"Elizabeth M.","family":"Swisher","sequence":"first","affiliation":[{"name":"Department of Obstetrics &amp; Gynecology, University of Washington, Seattle, WA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6083-657X","authenticated-orcid":true,"given":"Gottfried","family":"Konecny","sequence":"additional","affiliation":[{"name":"University of California, Los Angeles Jonsson Comprehensive Cancer Center, Los Angeles, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9454-3254","authenticated-orcid":true,"given":"Joshua","family":"Cohen","sequence":"additional","affiliation":[{"name":"City of Hope National Medical Center, Duarte, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9159-2421","authenticated-orcid":true,"given":"Gerardo","family":"Colon-Otero","sequence":"additional","affiliation":[{"name":"Division of Hematology &amp; Oncology, Mayo Clinic, Jacksonville, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2642-7160","authenticated-orcid":true,"given":"Natalie","family":"Danziger","sequence":"additional","affiliation":[{"name":"Foundation Medicine, Inc, Cambridge, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0105-9760","authenticated-orcid":true,"given":"Douglas I.","family":"Lin","sequence":"additional","affiliation":[{"name":"Foundation Medicine, Inc, Cambridge, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5617-6262","authenticated-orcid":true,"given":"Gerald","family":"Li","sequence":"additional","affiliation":[{"name":"Foundation Medicine, Inc, Cambridge, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia C. F.","family":"Quintanilha","sequence":"additional","affiliation":[{"name":"Foundation Medicine, Inc, Cambridge, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4516-7421","authenticated-orcid":true,"given":"Brennan","family":"Decker","sequence":"additional","affiliation":[{"name":"Foundation Medicine, Inc, Cambridge, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8494-2596","authenticated-orcid":true,"given":"Jeffrey S.","family":"Ross","sequence":"additional","affiliation":[{"name":"Foundation Medicine, Inc, Cambridge, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary","family":"Gearing","sequence":"additional","affiliation":[{"name":"Foundation Medicine, Inc, Cambridge, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathryn","family":"Baker","sequence":"additional","affiliation":[{"name":"Foundation Medicine, Inc, Cambridge, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takara","family":"Scott","sequence":"additional","affiliation":[{"name":"Foundation Medicine, Inc, Cambridge, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynette","family":"Poyser","sequence":"additional","affiliation":[{"name":"Foundation Medicine, Inc, Cambridge, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7627-6984","authenticated-orcid":true,"given":"Paul","family":"Vallejos","sequence":"additional","affiliation":[{"name":"Foundation Medicine, Inc, Cambridge, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9476-9563","authenticated-orcid":true,"given":"Julia A.","family":"Elvin","sequence":"additional","affiliation":[{"name":"Foundation Medicine, Inc, Cambridge, MA"},{"name":"AstraZenaca, Cambridge, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8065-4148","authenticated-orcid":true,"given":"Ryon P.","family":"Graf","sequence":"additional","affiliation":[{"name":"Foundation Medicine, Inc, Cambridge, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","reference":[{"key":"e_1_3_9_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-023-00970-w"},{"key":"e_1_3_9_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2021.08.030"},{"key":"e_1_3_9_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature06548"},{"key":"e_1_3_9_5_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-0419"},{"key":"e_1_3_9_6_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0715"},{"key":"e_1_3_9_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.34.2980"},{"key":"e_1_3_9_8_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-1178"},{"key":"e_1_3_9_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature06633"},{"key":"e_1_3_9_10_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-0088"},{"key":"e_1_3_9_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.02.008"},{"key":"e_1_3_9_12_2","doi-asserted-by":"publisher","DOI":"10.7150\/jca.65650"},{"key":"e_1_3_9_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2022.08.021"},{"key":"e_1_3_9_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103684"},{"key":"e_1_3_9_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1810858"},{"key":"e_1_3_9_16_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01003"},{"key":"e_1_3_9_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910962"},{"key":"e_1_3_9_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.05.005"},{"key":"e_1_3_9_19_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-1225"},{"key":"e_1_3_9_20_2","author":"Database Characterization Guide","year":"2025","unstructured":"Database Characterization Guide: Flatiron Health, 2025","journal-title":"Flatiron Health"},{"key":"e_1_3_9_21_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.3241"},{"key":"e_1_3_9_22_2","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.2696"},{"key":"e_1_3_9_23_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0264138"},{"key":"e_1_3_9_24_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.5576"},{"key":"e_1_3_9_25_2","article-title":"Pan-cancer analysis of copy-number features identifies recurrent signatures and a homologous recombination deficiency biomarker to predict poly (ADP-Ribose) polymerase inhibitor response","author":"Moore JA","unstructured":"Moore JA, Chen KT, Madison R, et al: Pan-cancer analysis of copy-number features identifies recurrent signatures and a homologous recombination deficiency biomarker to predict poly (ADP-Ribose) polymerase inhibitor response. JCO Precis Oncol 10.1200\/PO.23.00093","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_9_26_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature15393"},{"key":"e_1_3_9_27_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2213457"},{"key":"e_1_3_9_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/1475-6773.13669"},{"key":"e_1_3_9_29_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-022-02091-8"},{"key":"e_1_3_9_30_2","doi-asserted-by":"publisher","DOI":"10.1158\/2767-9764.CRC-22-0161"},{"key":"e_1_3_9_31_2","article-title":"Tumor mutational burden as a predictor of first-line immune checkpoint inhibitor versus carboplatin benefit in cisplatin-unfit patients with urothelial carcinoma","author":"Graf RP","unstructured":"Graf RP, Fisher V, Huang RSP, et al: Tumor mutational burden as a predictor of first-line immune checkpoint inhibitor versus carboplatin benefit in cisplatin-unfit patients with urothelial carcinoma. JCO Precis Oncol 10.1200\/PO.22.00121","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_9_32_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.52244"},{"key":"e_1_3_9_33_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2009.00600.x"},{"key":"e_1_3_9_34_2","volume-title":"Guidance Document: Real-World Evidence: Considerations Regarding Non-Interventional Studies for Drug and Biological Products","author":"FDA","year":"2024","unstructured":"FDA: Guidance Document: Real-World Evidence: Considerations Regarding Non-Interventional Studies for Drug and Biological Products, 2024"},{"key":"e_1_3_9_35_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-2228"},{"key":"e_1_3_9_36_2","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010311"},{"key":"e_1_3_9_37_2","unstructured":"FDA. FoundationOneCDx Technical Information"},{"key":"e_1_3_9_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30559-9"},{"key":"e_1_3_9_39_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22582-6"},{"key":"e_1_3_9_40_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1506859"}],"container-title":["JCO Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/PO-25-00763","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T19:59:14Z","timestamp":1778788754000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/PO-25-00763"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1200\/PO-25-00763"],"URL":"https:\/\/doi.org\/10.1200\/po-25-00763","relation":{},"ISSN":["2473-4284"],"issn-type":[{"value":"2473-4284","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"2025-08-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-27","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e2500763"}}